Month 4: Steady Progress (1 mg dose) Average weight loss: 6-8% cumulative (12-16 pounds for a 200-pound person) Around week 12-16, your provider will increase your dose to 1 mg weekly
Furthermore, treatment with tirzepatide was associated with greater reductions in mean percent body weight, mean waist circumference and WHtR compared with semaglutide, with a higher proportion of tirzepatide-treated participants achieving all body weight reduction thresholds
10.1016/j.cmet.2023.11.009 85 XuR.LiuB.ZhouX
Mounjaro, also a GLP-1, is a brand name for the drug tirzepatide thats FDA-approved to improve glucose in people with type 2 diabetes
Readers are strongly encouraged to consult with licensed healthcare providers before beginning any weight loss regimen, including the use of GLP-1 medications such as semaglutide, Ozempic, or similar treatments